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Summary
Background Pegvisomant is a new growth hormone receptor
antagonist that improves symptoms and normalises insulin-
like growth factor-1 (IGF-1) in a high proportion of patients
with acromegaly treated for up to 12 weeks. We assessed
the effects of pegvisomant in 160 patients with acromegaly
treated for an average of 425 days.
Methods Treatment efficacy was assessed by measuring
changes in tumour volume by magnetic resonance imaging,
and serum growth hormone and IGF-1 concentrations in 152
patients who received pegvisomant by daily subcutaneous
injection for up to 18 months. The safety analysis included
160 patients some of whom received weekly injections and
are excluded from the efficacy analysis.
Findings Mean serum IGF-1 concentrations fell by at least
50%: 467 g/L (SE 24), 526 g/L (29), and 523 g/L (40)
in patients treated for 6, 12 and 18 months, respectively
(p<0·001), whereas growth hormone increased by 12·5 g/L
(2·1), 12·5 g/L (3·0), and 14·2 g/L (5·7) (p<0·001). Of
the patients treated for 12 months or more, 87 of 90 (97%)
achieved a normal serum IGF-1 concentration. In patients
withdrawn from pegvisomant (n=45), serum growth hormone
concentrations were 8·0 g/L (2·5) at baseline, rose to 15·2
g/L (2·4) on drug, and fell back within 30 days of
withdrawal to 8·3 g/L (2·7). Antibodies to growth hormone
were detected in 27 (16·9%) of patients, but no tachyphylaxis
was seen. Serum insulin and glucose concentrations were
significantly decreased (p<0·05). Two patients experienced
progressive growth of their pituitary tumours, and two 
other patients had increased alanine and asparate
aminotransferase concentrations requiring withdrawal from
treatment. Mean pituitary tumour volume in 131 patients
followed for a mean of 11·46 months (0·70) decreased by
0·033 cm3 (0·057; p=0·353).
Interpretation Pegvisomant is an effective medical treatment
for acromegaly. 
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Introduction
Current treatments for acromegaly, which is usually
caused by an adenoma of the pituitary, attempt to control
the disease by reducing growth hormone secretion from
the tumour either by surgery, radiotherapy, or
medication. Unfortunately, when strict biochemical
criteria are applied, surgery cures only 60% of patients
overall, and less than half of patients with
macroadenomas, which represent most cases seen.1,2
The role of radiotherapy remains limited owing to 
slow onset of effect, ineffectiveness in normalising 
IGF-1 concentrations, and a high occurence of
panhypopituitarism.3–5 Current medical therapy is also
less effective than desired. Dopamine agonists rarely
normalise growth hormone and IGF-1, and have side-
effects that limit long-term tolerability and compliance.6,7
Somatostatin analogues, such as octreotide or
lanreotide, bind to somatostatin receptors present on the
tumour, and inhibit growth hormone secretion.
However, IGF-1 is normalised in only about 65% of
patients.8–11
Pegvisomant (B2036–PEG; Sensus Drug Development
Corporation, Austin, TX, USA) is a new, genetically-
engineered analogue of human growth hormone which
functions as a highly selective growth hormone receptor
antagonist.12,13 In a 12 week, placebo-controlled study,14
clinical symptoms were significantly improved and 
serum IGF-1 concentrations normalised in 89% of
acromegalic patients treated with pegvisomant. However,
serum growth hormone concentrations also increased
substantially in compensation, raising the questions of
whether additional increases in serum growth hormone
concentrations might occur if treatment was prolonged,
whether a sustained increase in serum growth hormone
might overcome the receptor-blocking action of the drug
(ie, induce tachyphylaxis), or whether the increase in
growth hormone might be accompanied by growth of 
the pituitary tumour.15 The long-term efficacy of
pegvisomant is also thought to be compromised by the
development of antibodies to growth hormone or to
pegvisomant. We report here the results of an analysis of
the long-term safety and efficacy of pegvisomant in 160
patients with acromegaly treated for up to 18 months.
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Patients and methods
Patients
We screened patients with acromegaly, aged 18 years or
older, at the participating clinics. At the first screening
visit treatment with somatostatin analogues and dopamine
agonists was discontinued in the patients receiving these
drugs. A second screening visit took place a minimum of 2
weeks after discontinuation of somatostatin analogues and
5 weeks after discontinuation of dopamine agonists.
Patients were eligible for enrolment if their serum IGF-1
concentration at that visit was at least 1·3 times the upper
limit of the age-adjusted normal range, according to local
laboratory values. The study protocols were approved by
the human research committee at each site, and all
patients gave written informed consent before
confirmation of eligibility.
Methods
Patients received pegvisomant as a once daily
subcutaneous injection according to one of two clinical
protocols (SEN-3613A and SEN-3614/15). 38 patients
initially received weekly dosing (protocol SEN-3611/13)
before being switched to daily dosing (protocol SEN-
3613A). Only their daily dosing data are included in the
efficacy analysis. Patients participating in protocol SEN-
3614/15 received only daily dosing.
Daily dosing in both protocols began at 10 mg per day
and was titrated up or down as necessary in 5 mg per day
increments until the patient’s serum IGF-1 concentration
was normal or a maximum dose of 40 mg per day was
reached. In SEN-3613A, the minimum dose titration
interval was 2 weeks after the last dosing change. In SEN-
3614/15, the dose adjustment was permitted no sooner
than 8 weeks after the last dosing change. The 12 week,
placebo-controlled data for patients who initially received
pegvisomant in protocol SEN-3614/15 have been
previously reported. 14
All data from patients with acromegaly exposed to
pegvisomant in the clinical development programme were
included in the safety analysis. Safety assessments
included: serum concentrations of alkaline phosphatase,
alanine aminotransferase, aspartate transaminase, lactate
dehydrogenase, total bilirubin, blood urea nitrogen,
creatinine, cholesterol, triglycerides, and haemoglobin;
white blood cell count; and platelet count;
electrocardiograms; chest radiographs; and vital signs. If a
patient had a gap in pegvisomant administration of more
than 1 month, each dosing period was treated separately
for the purposes of evaluating clinical laboratory results;.
this situation occurred in 26 patients. Adverse events were
recorded at each visit. Pituitary tumour volumes were
assessed16 by a single neuroradiologist (RKH) who was
unaware of treatment assignment and dose of
pegvisomant, using magnetic resonance imaging obtained
at the baseline visit before pegvisomant treatment, and
from the most recently obtained image at the cut-off date
for the analysis.
To assess the effect of pegvisomant on serum
concentrations of IGF-1 and growth hormone, patients
from the two daily dosing protocols were placed in cohorts
on the basis of whether they had completed at least 6, 12,
or 18 months of continuous daily pegvisomant treatment
at the time of data cut-off. The cohorts were constructed
in a cumulative fashion, such that all the patients in the 18
month treatment cohort were also included in the 6 and
12 month cohorts, and the patients in the 12 month
cohort were also included in the 6 month cohort. For all
cohorts, the baseline visit was regarded as the visit that
occurred immediately before starting pegvisomant therapy
in the initial study protocol. Age-adjusted normal limits
for IGF-1 were used. Antibodies to growth hormone were
measured at about monthly intervals throughout
treatment in all patients. Because pegvisomant interfered
with the assay, the measurement of pegvisomant
antibodies was made in samples obtained after
pegvisomant treatment had been discontinued for a
month.
Serum IGF-1 was measured by a competitive binding
radioimmunoassay (Nichols Institute Diagnostics, San
Juan Capistrano, CA, USA). Serum growth hormone was
measured using antiserum saturated with B2036 (the
protein component of pegvisomant) to eliminate cross-
reactions with pegvisomant. The sensitivity of the assay
was 0·5 g/L, with an inter-assay coefficient of variation
of 16% (Endocrine Sciences, Calabasas Hills, California,
USA). Antibodies to growth hormone were measured by
radioimmunoassay (Endocrine Sciences). Antibodies to
pegvisomant were assessed in a semi-quantitative
screening assay by use of radiolabelled pegvisomant and a
polyethylene glycol precipitation system. The assays for
serum IGF-1, growth hormone and antibodies to growth
hormone and and pegvisomant were done by a single
laboratory (Endocrine Sciences). Serum pegvisomant
concentrations were measured by a specific
radioimmunoassay (Phoenix International Life Sciences,
Saint-Laurent, Quebec, Canada). All other clinical
laboratory samples were analysed with standard
commercial assays.
Statistical analysis
The assumption of the normality of the IGF-1, growth
hormone, insulin, glucose and glycated haemoglobin data
was investigated by use of a Shapiro-Wilks test, in which
the null hypothesis that the data represented a random
sample from the normal distribution was rejected.
Therefore, the Wilcoxon’s signed rank test, which is a
non-parametric analogue to the paired-difference t test,
was used for assessing the statistical significance of the
changes from baseline for these measures.
Role of the funding source
The study was financed and designed by Sensus Drug
Development Corporation, Austin, Texas, USA.
Results
167 patients with acromegaly participated in the
pegvisomant clinical development programme. Seven of
these patients received only placebo and are not otherwise
reported here. Three of the remaining 160 patients
received only a single dose of the drug, and five received
only weekly doses (range 30–80 mg per week) during the
course of early phase II studies. Although included in
safety analysis, these patients’ efficacy data have been
excluded from this report. Table 1 shows the patients’
demographic characteristics and acromegaly treatment
before enrolment in the initial pegvisomant study. Of the
160 patients exposed to pegvisomant, 30 withdrew
prematurely (two for protocol violations, nine for adverse
events, five for lack of efficacy, two lost to follow up, and
12 as voluntary withdrawals). There were no clinically
significant differences in demographics or prior treatment
histories for the cohorts. However, the mean serum IGF-1
and growth hormone concentrations at baseline were
substantially higher for the cohort of patients treated for
more than 18 months than for the group as a whole (160),
reflecting the more severe nature of the disease in the
patients entered in the earliest phase of clinical
development. The group as a whole accumulated 186
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patient-years of exposure to pegvisomant, with a mean
treatment duration of 425 days.
The dose-titrated decreases in serum IGF-1
concentrations required by the protocols was achieved in
the three cohorts (figure 1). The mean serum
pegvisomant trough concentrations were 12·25 mg/L (SE
0·73) in patients treated for 6 months, 17·57 mg/L (1·28)
in those treated for 12 months, and 19·06 mg/L (2·82) in
those treated for 18 months. The mean doses were 14·7
mg per day (0·4), 18·0 mg per day (0·7), and 19·6 mg per
day (1·4), respectively. Normal serum IGF-1
concentration was achieved in 87 of 90 (97%) of patients
treated for 12 months or more. Figure 2 shows the lowest
value of serum IGF-1 concentration achieved during
pegvisomant treatment for this cohort. To assess
durability of the pegvisomant response (presence or
absence of tachyphylaxis), an analysis of the 38 patients
treated daily with pegvisomant for an average of 83 weeks
showed that the serum IGF-1 concentrations were within
normal limits in 572 of the 624 post-baseline visits
(91·7%). Mean serum growth hormone concentrations at
baseline were 10·9 g/L (SE 1·5), 13·2 g/L (2·1), and
19·2 g/L (4·3) in the 6, 12, and 18 month cohorts. On
average, these increased by 12·5 g/L (2·1), 12·5 g/L
(3·1), and 14·2 g/L (5·7) to 23·1 g/L (3·1), 25·6 g/L
(4·3), and 33·8 g/L (8·6), respectively (p<0·05 for
within-cohort, baseline vs final comparisons), with the
time course of the increases mirroring the falls in serum
IGF-1 concentrations (figure 1). In a subgroup of patients
who were withdrawn from pegvisomant and not placed on
alternative medical therapy for at least one month (n=45),
the mean serum growth hormone concentration was
8·0 g/L (2·5) at baseline, rose to 15·2 g/L (2·4) at the
last visit before withdrawal, and fell back within 30 days of
withdrawal to 8·3 g/L (2·7) (p=0·6739 compared with
baseline).
27 patients (16·9%) had one or more samples test
positive for antibodies to pegvisomant. 11 of these 27
patients had only single increases in titres ranging from
1:4 to 1:16. Three patients who had sustained low titres of
antibodies to growth hormone normalised their serum
IGF-1 concentration within 2 months of beginning
treatment; their IGF-1 concentrations remained normal
despite persistent, low antibody titres. In the remaining 13
patients, antibodies to growth hormone appeared
sporadically during the course of therapy. In 39 patients,
samples were taken about 1–2 months after stopping
pegvisomant treatment (as confirmed by serum
pegvisomant assay) and were analysed for pegvisomant
antibodies. Samples from ten patients tested positive in
titres ranging from 1:8 to 1:256. In all of these patients,
antibodies to growth hormone were also present, either
during or after treatment. Nine of these patients
normalised their IGF-1 and none showed evidence of
tachyphylaxis.
Fasting serum insulin concentrations fell from
23·0 mU/L (SE 4·1) to 15·8 mU/L (3·6) in the 6 month
cohort (p=0·0717), from 23·0 mU/L (4·1) to 12·4 mU/L
(2·5) in the 12 month cohort (p=0·0075), and 23·3 mU/L
(6·3) to 12·4 mU/L (2·2) in the 18 month cohort
(p=0·0393). Fasting serum glucose concentrations also
decreased from 1053 mg/L (74) to 862 mg/L (19·8) in the
6 month group (p=0·0130), from 1053 mg/L (74) to
906 mg/L (23) in the 12 month group (p=0·0531), and
984 mg/L (34) to 904 mg/L (21) in the 18 month cohort
(p=0·0125). The glycated haemoglobin concentrations
did not change significantly (from 5·7% [0·1], 5·7% [0·1],
and 5·4% [0·1] to 5·7% [0·1], 5·8% [0·1], and 5·7%
[0·1], respectively). 
Adverse effects reported in more than 10% of the
patients are displayed in table 2. Injection-site reactions
were reported by 18 patients (11%) and were generally
characterised as mild, erythematous, self-limited reactions
that did not require treatment. The infections reported
were generally non-serious, upper-respiratory-tract
infections that rarely required treatment, with the
exception of seven cases of pneumonia, a gluteal abscess,
and a case of urosepsis. Two patients had increased
concentrations of alanine aminotransferase, and aspartate
transaminase of more than ten-fold above the upper limit
of normal within 12 weeks of beginning pegvisomant
therapy, and as a consequence were withdrawn. Both
were symptom-free except for mild fatigue, and had
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Characteristics All patients (n=160) Daily dosing
All (n=152) 6 month cohort 12 month cohort 18 month cohort
(n=131) (n=90) (n=39)
Age, years† 46±14 46±14 46±14 44±13 42±13
Men 94 (59%) 87 (57%) 75 (57%) 47 (52%) 18 (46%)
Women 66 (41%) 65 (43%) 56 (43%) 43 (48%) 21 (54%)
Duration of disease, years† 8 (8) 8 (8) 8 (8) 8 (7) 8 (8)
Previous therapy
Surgery 134 (84%) 130 (86%) 111 (85%) 82 (91%) 35 (90%)
Radiation 94 (59%) 89 (56%) 78 (60%) 57 (63%) 26 (67%)
Somatostatin analogue 117 (73%) 112 (74%) 97 (74%) 74 (82%) 33 (85%)
Dopamine agonist 76 (48%) 73 (48%) 67 (51%) 48 (53%) 19 (48%)
Bodyweight, kg† 94 (21) 94 (21) 94 (21) 93 (20) 92 (19)
Growth hormone, g/L† 10·2 (16·0) 10·4 (16·3) 10·9 (17·0) 13·2 (19·7) 19·2 (27·0)
IGF-1 g/L† 762 (330) 755 (327) 760 (306) 806 (297) 847 (321)
Pituitary tumour volume, cm3† 2·39 (3·45) 2·36 (3·48) 2·14 (2·47) 2·44 (2·70) 2·49 (2·58)
†Values are means (SD).



































Figure 1: Serum concentrations of insulin-like growth factor-1
and growth hormone 
For personal use. Only reproduce with permission from The Lancet Publishing Group.
normal bilirubin concentrations throughout. Liver
enzyme concentrations returned to normal within several
months after stopping the drug. As previously reported,14
one of the two had a further rise in these enzyme
concentrations on rechallenge with pegvisomant.
The mean serum concentrations of blood urea nitrogen,
creatinine, bilirubin, alanine aminotransferase, asparate
aminotransferase, alkaline phosphatase, lactate
dehydrogenase, and triglyceride; haematocrit; white blood
cell count; and platelet counts were within normal limits
at baseline and did not change during treatment (data not
shown). No clinically significant changes were noted in
vital signs, electrocardiograms, or chest radiographs (data
not shown). Mean total serum cholesterol concentrations
at baseline (5·23 mmol/L [SE 0·08]) were above the
recommended level for therapeutic intervention (5·14
mmol/L), but did not change substantially during the
course of pegvisomant treatment (5·18 mmol/L [0·11] in
patients treated for >12 months). Hypercholesterolaemia
was reported as an adverse event in 23 patients (table 2),
although 18 of these patients had serum total cholesterol
concentrations greater than 5·14 mmol/L at baseline. 
Baseline magnetic resonance imaging (MRI) scans were
available for 149 patients before treatment with
pegvisomant: 59 (40%) had tumours smaller than 1 cm3
baseline. Paired sets of the baseline and the most recent
scans were available for 131 patients. The mean tumour
volume did not decrease signficantly (2·41 cm3 [SE 0·31]
at baseline to 2·37 cm3 [0·31], a mean change from
baseline of –0·033 cm3 [0·057]; p=0·353). The mean
duration between baseline and final scan was 11·46
months (0·70). In 78 patients previously treated with
radiation therapy the mean tumour volume decreased by
–0·126 cm3 (0·071) over 12·48 months (0·99; p=0·214).
In 53 patients previously untreated with radiation therapy
the mean tumour volume increased by 0·103 cm3 (0·093)
over 9·97 months (0·90; p=0·948). There was no
association between the duration of pegvisomant
treatment and change in tumour volume (figure 3). For all
patients who had at least 12 months between their
baseline and final scan, the results were similar with a
mean change of –0·067 cm3 (0·103; p=0·064).
Two patients required treatment owing to progression
in tumour size, the cause of which was unclear. Both had
large, globular tumours with impingement on the optic
chiasm at baseline despite recent prior trans-sphenoidal
surgery. The first patient had a baseline tumour volume of
5·53 cm3 just before treatment. The tumour volume after
3 months of pegvisomant at 15 mg/day was 5·66 cm3. The
patient was off pegvisomant for 6 months and then
restarted, but unfortunately the MRI taken at the time of
restart was found to have motion artefact, preventing an
accurate calculation of tumour volume. At the next
scheduled MRI examination 6 months later, the tumour
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Figure 2: Baseline and lowest values of individual serum insulin-like growth factor-1 concentrations achieved in 90 patients treated
for 12 months or more with daily pegvisomant 




Accidental injury 28 (18)
Pain 36 (23)
Influenza-like syndrome 33 (21)
Injection site reaction 18 (11)






Table 2: Adverse effects occurring in at least 10% of patients
treated with pegvisomant (n=160) 
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volume was 8·71 cm3, prompting treatment with
radiotherapy. The second patient, who is the subject of a
published case report, 17 had a baseline tumour volume of
2·93 cm3 before treatment, and was treated with weekly
doses of 80 mg pegvisomant for 3 months, during which
time the tumour volume decreased to 2·75 cm3. The
patient was then treated with octreotide for 5 months and
subsequently switched back to pegvisomant. An MRI scan
was not obtained until 2 months after the switch, at which
time the tumour volume was calculated to be 4·28 cm3. A
scan obtained 11 months after the restart of pegvisomant
showed a tumour volume of 4·92 cm3. 16 months after the
restart of pegvisomant, octreotide was added to the
regimen because of the onset of visual symptoms and
incomplete control of the patient’s serum IGF-1
concentration. An MRI scan obtained at that time could
not be used to calculate tumour volume. The next MRI
scan, obtained 6 months after the start of combined
pegvisomant and octreotide treatment, showed a tumour
volume of 5·41 cm3. Pegvisomant was discontinued,
resulting in a substantial rise in serum 
IGF-1 concentrations, accompanied by recurrence of
headaches, fatigue, diaphoresis and other symptoms of
active acromegaly, despite continued maximum doses of
octreotide. The patient therefore underwent a second
trans-sphenoidal procedure to debulk the tumour mass.
Discussion
The size of the reduction in serum IGF-1 concentrations
at 12 and 18 months was similar to that seen in patients
treated with pegvisomant 20 mg/day in a prior, well
controlled 12 week study.14 The 97% response rate is high
compared with the approximately 65% obtained with
existing medical therapies such as dopamine agonists6,7
and somatostatin analogues.8–11 The greater size and
predictability of the response is a result of pegvisomant’s
mechanism of action as a growth hormone receptor
antagonist, in which the effect of excess growth hormone
is blocked at a cellular level, thus reducing growth
hormone action rather than relying on inhibition of
growth hormone secretion from the tumour. The response
to pegvisomant is therefore not dependent on tumour
expression of fully functional somatostatin receptors,18 nor
is it affected by somatostatin receptor type-specificity.19 A
recent report has confirmed pegvisomant’s effectiveness in
patients with acromegaly resistant to dopamine agonists
and somatostatin analogues.20
The rise in mean serum growth hormone
concentrations temporally mirrored the fall in serum IGF-
1 concentrations, and after the first observation made at
6 months, did not continue to increase (figure 1). This
observation was similar to that made in the previous
study,14 in which the rise in growth hormone was seen at
the first post-baseline visit, 2 weeks after initiation of
pegvisomant therapy, with no significant subsequent rise.
The mechanism responsible for the rise in growth
hormone is unknown, although it might be related to the
fall in serum IGF-1 concentrations since, in the subgroup
of patients (n=45) who were withdrawn from pegvisomant
and not placed on alternative medical therapy for
1 month, serum growth hormone concentrations fell back
to baseline. 
Mean pituitary tumour volumes did not change in
patients followed up on average for 11·5 months,
irrespective of the patients’ previous history of radiation
therapy. Although two patients required treatment due to
progression in tumour size, there was no association
between the duration of pegvisomant treatment and
change in tumour volume. These observations form the
basis for some optimism that patients treated with
pegvisomant will not develop a Nelson’s syndrome-like
effect, in which interruption of growth hormone-mediated
negative feedback on the tumour via blockade of the
growth hormone receptor might result in later onset of
tumour growth. However, because Nelson’s syndrome
can become apparent after many years, and because
pituitary tumours in patients with acromegaly are usually
slow-growing, long-term monitoring of tumour volumes
using MRI scans is prudent in patients treated with
pegvisomant, as would be the case with any patient with
acromegaly treated medically. 
Pegvisomant was generally well tolerated. The 30% rate
of generally mild infections probably reflects the relatively
long period of intense follow-up of these patients.
However, since the data are uncontrolled, no firm
conclusions can be drawn as to the potential for infection
in patients treated with the drug. The observation that
two patients had raised liver aminotransferases requiring
discontinuation of the drug, suggests that caution is
warranted and liver function should be monitored until a
larger number of patients have been exposed to the drug.
Since 11 of the 90 patients treated for more than 1 year
had serum IGF-1 concentrations that fell below the lower
limit of the age-adjusted normal range, with nine
requiring a downward titration of their dose, IGF-1
should also be monitored frequently and the dose
adjusted to keep the serum IGF-1 concentration within
the normal range. In contrast, the serum growth hormone
concentration is not a useful marker of disease activity
status in pegvisomant-treated patients.
Other metabolic consequences of acromegaly could be
improved by blocking the growth hormone receptor with
pegvisomant. Excess growth hormone is associated with
insulin resistance in animals, presumably as a result of
interference with insulin signal transduction.21 Patients
with acromegaly are also insulin resistant,22 and up to 30%
of untreated patients with acromegaly have been reported
to develop type 2 diabetes.23 In the current analysis,
fasting serum insulin and glucose concentrations fell
significantly in patients treated with pegvisomant for up to
18 months, despite none of these patients being overtly
diabetic at baseline. Pegvisomant has also been shown to
influence the development of experimental diabetic
nephropathy,24–27 warranting further investigation of the
drug’s effects on insulin and carbohydrate metabolism in
patients without acromegaly.
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Figure 3: Lack of association between duration of pegvisomant
treatment and change in tumour volume on the most recent
MRI scan obtained while on pegvisomant 
=previous radiation therapy. =no previous radiation therapy.
For personal use. Only reproduce with permission from The Lancet Publishing Group.
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